May 2005
Volume 46, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2005
Intraocular Pressure After Intravitreal Triamcinolone Acetonide for Diabetic Diffuse Macular Edema
Author Affiliations & Notes
  • V. Gualino
    Hôpital Lariboisière, Université Denis Diderot, Paris, France
  • F. Audren
    Hôpital Lariboisière, Université Denis Diderot, Paris, France
  • A. Erginay
    Hôpital Lariboisière, Université Denis Diderot, Paris, France
  • B. Haouchine
    Hôpital Lariboisière, Université Denis Diderot, Paris, France
  • J. Bergmann
    Hôpital Lariboisière, Université Denis Diderot, Paris, France
  • A. Gaudric
    Hôpital Lariboisière, Université Denis Diderot, Paris, France
  • P.G. Massin
    Hôpital Lariboisière, Université Denis Diderot, Paris, France
  • Footnotes
    Commercial Relationships  V. Gualino, None; F. Audren, None; A. Erginay, None; B. Haouchine, None; J. Bergmann, None; A. Gaudric, None; P.G. Massin, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2005, Vol.46, 1433. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      V. Gualino, F. Audren, A. Erginay, B. Haouchine, J. Bergmann, A. Gaudric, P.G. Massin; Intraocular Pressure After Intravitreal Triamcinolone Acetonide for Diabetic Diffuse Macular Edema . Invest. Ophthalmol. Vis. Sci. 2005;46(13):1433.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: To evaluate prospectively the effect on intraocular pressure (IOP) of intravitreal injection of 4mg triamcinolone acetonide (TA) for refractory diffuse diabetic macular edema. Methods: Diabetic patients included in 2 prospective randomized trials received an intravitreal injection of 4 mg TA. All eyes had diabetic macular edema unresponsive to laser photocoagulation. To detect corticosteroid–induced ocular hypertension, one month of treatment with topical 0.1% dexamethasone three times daily in both eyes of all patients was administered before inclusion. TA injection was performed only if IOP rise under dexamethasone treatment did not exceed 15mmHg. IOP, measured before and after dexamethasone treatment, before and at various times after injection, the need of an antiglaucomatous treatment, the time of occurrence of ocular hypertension if ever, were studied. Results:Thirty–five eyes of 35 patients were injected. Follow–up after injection was at least 24 weeks for all patients. A IOP superior to 24 mmHg was observed in 17 eyes (48,6%) at a mean time after injection of 38.3 ± 34.8 days (2 to 113). In all cases, ocular hypertension was controlled by topical treatment. Before and after dexamethasone treatment, mean ± SD PIO was 15.7 ± 2.4 mmHg (10 to 20) and 18.2 ± 2.5 µm (15 to 22) respectively (p=0.0015, Wilcoxon test for paired samples) in the group of eyes which experienced IOP superior to 24 mmHg. Before and after dexamethasone treatment, mean ± SD PIO was 15.7 ± 3.0 mmHg (12 to 22) and 16.7 ± 3.0 mmHg (10 to 23) respectively (p=0.0015, Wilcoxon test for paired samples) in the group of eyes which did not experienced IOP superior to 24 mmHg (p> 0.08). Conclusions: Intravitreal injection of triamcinolone induces a IOP rise in almost half cases in our series of eyes with diabetic macular edema. Our results allows to discuss the value of a predictive test with topical dexamethasone for glucocorticoid–induced hypertension. The rise of IOP with the test is significant, but its magnitude is low, which can limit its use. Further studies are warranted..

Keywords: diabetic retinopathy • corticosteroids • macula/fovea 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×